FDA plans to study whether frequent viewing of a TV ad effects viewer perception of risks and benefits; costing $1.2 million, it is the sixth DTC ad study to be announced this year.
In its latest study of direct-to-consumer Rx drug advertisements, FDA plans to assess whether frequent viewing of an ad impacts viewer perception of its risk and benefit information.
FDA notes that the perceptual and cognitive effects of increasing the frequency of ad exposure has been studied extensively using...
Industry experts forecast the impact of President Trump's Most-Favored Nation drug pricing policy on the commercial insurance industry.
New members of the CDC’s Advisory Committee on Immunization Practices suggested concerns beyond myocarditis, questioning whether test-negative observational studies are giving an incorrect picture of effectiveness.
The plan could curtail a period of pricing flexibility for newer subcutaneous versions of important oncology drugs.
Extended-release stimulants will add a new ‘Limitation of Use’ about weight loss in children under 6 years, reflecting concerns about overuse from the Make America Healthy Again commission, a concern multiple studies did not find valid.
New rules requiring more granular drug pricing data to be disclosed in machine-readable files will go into effect in 2026.
The budget reconciliation bill nears final passage without pharmacy benefit manager reforms or provisions that would facilitate access to cell and gene therapies for children, but its Medicaid cuts pose a significant threat to prescription drug access.
Roche’s filing for Elevidys in the EU followed applications in Middle Eastern countries because those markets accept applications based on approval by the US Food and Drugs Administration.
